Amedeo Smart

Free Medical Literature Service

 

Amedeo

Head and Neck Cancer
  Free Subscription

Articles published in
J Clin Oncol
    September 2025
  1. LU Z, Du W, Jiao X, Wang Y, et al
    Reply to: "NOTCH1: A Potential New Biomarker in the Era of Immunotherapy?" and "Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma".
    J Clin Oncol. 2025 Sep 11:JCO2501535. doi: 10.1200/JCO-25-01535.
    >> Share

  2. LU Z, Yan K, Sheng Y, Rukonge PA, et al
    Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma.
    J Clin Oncol. 2025 Sep 11:JCO2501053. doi: 10.1200/JCO-25-01053.
    >> Share

  3. BOURHIS J, Licitra LF, Burtness B, Psyrri A, et al
    Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.
    J Clin Oncol. 2025 Sep 3:JCO2500272. doi: 10.1200/JCO-25-00272.
    >> Share

  4. DOUGAN M, Dougan SK
    Second Mitochondrial Activator of Caspases Mimetics Accelerate Progression of Locally Advanced Head and Neck Cancer.
    J Clin Oncol. 2025 Sep 3:JCO2501024. doi: 10.1200/JCO-25-01024.
    >> Share

    August 2025
  5. BURTNESS B, Flamand Y, Quon H, Weinstein GS, et al
    Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer.
    J Clin Oncol. 2025;43:2559-2565.
    >> Share

  6. SHITARA K, Lorenzen S, Li J, Bai Y, et al
    Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study.
    J Clin Oncol. 2025;43:2502-2514.
    >> Share

    July 2025
  7. VAN DEN BOSCH S, Hannink G, Kaanders JHAM
    Reply to: Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT.
    J Clin Oncol. 2025 Jul 22:JCO2501390. doi: 10.1200/JCO-25-01390.
    >> Share

  8. KIYOTA N, Mizusawa J, Zenda S, Yokota T, et al
    Caution Needed Before Adopting Reduced-Dose Elective Neck Irradiation in Head and Neck Cancer: A Response to UPGRADE-RT.
    J Clin Oncol. 2025 Jul 22:JCO2500928. doi: 10.1200/JCO-25-00928.
    >> Share

  9. KAWAKAMI H, Kadowaki S, Makiyama A, Tsuda M, et al
    Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.
    J Clin Oncol. 2025;43:2184-2195.
    >> Share

    May 2025
  10. ZANDBERG DP, Vujanovic L, Clump DA, Isett BP, et al
    Randomized Phase II Study of Concurrent Versus Sequential Pembrolizumab in Combination With Chemoradiation in Locally Advanced Head and Neck Cancer.
    J Clin Oncol. 2025 May 27:JCO2401580. doi: 10.1200/JCO-24-01580.
    >> Share

    April 2025
  11. VAN DEN BOSCH S, Doornaert PAH, Hoebers FJP, Kreike B, et al
    Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial.
    J Clin Oncol. 2025 Apr 15:JCO2402194. doi: 10.1200/JCO-24-02194.
    >> Share

  12. HOLSINGER FC, Ismaila N, Adkins DR, Barber BR, et al
    Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline.
    J Clin Oncol. 2025;43:1369-1392.
    >> Share

  13. LU Z, Du W, Jiao X, Wang Y, et al
    NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.
    J Clin Oncol. 2025 Apr 3:JCO2401818. doi: 10.1200/JCO-24-01818.
    >> Share

    February 2025
  14. YAYLALI M, Halac B, Yalcin B
    Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.
    J Clin Oncol. 2025 Feb 19:JCO2402689. doi: 10.1200/JCO-24-02689.
    >> Share

  15. SWIECICKI PL, Yilmaz E, Rosenberg AJ, Fujisawa T, et al
    Reply to: Enfortumab Vedotin: A Promising Therapy for Head and Neck Cancer With Potential Links to Human Papillomavirus.
    J Clin Oncol. 2025 Feb 19:JCO2500028. doi: 10.1200/JCO-25-00028.
    >> Share

    January 2025
  16. MACHTAY M, Torres-Saavedra PA, Thorstad W, Nguyen-Tan PF, et al
    Postoperative Radiotherapy +/- Cetuximab for Intermediate-Risk Head and Neck Cancer.
    J Clin Oncol. 2025 Jan 22:JCO2401829. doi: 10.1200/JCO-24-01829.
    >> Share

  17. KLEMPNER SJ, Sonbol MB, Wainberg ZA, Uronis HE, et al
    DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish.
    J Clin Oncol. 2025;43:339-349.
    >> Share

    December 2024
  18. NICHOLS AC, Theurer J, Prisman E, Read N, et al
    Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial.
    J Clin Oncol. 2024;42:4023-4028.
    >> Share

    October 2024
  19. SWIECICKI PL, Yilmaz E, Rosenberg AJ, Fujisawa T, et al
    Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer.
    J Clin Oncol. 2024 Oct 31:JCO2400646. doi: 10.1200/JCO.24.00646.
    >> Share

  20. TOPKAN E, Somay E, Bascil S, Pehlivan B, et al
    Underrated But Significant Risk Factors of Osteoradionecrosis of the Jaw in Patients With Head and Neck Cancer.
    J Clin Oncol. 2024 Oct 3:JCO2401020. doi: 10.1200/JCO.24.01020.
    >> Share

  21. CHEN WJ, Yu X, Lu YQ, Pfeiffer RM, et al
    Impact of an Epstein-Barr Virus Serology-Based Screening Program on Nasopharyngeal Carcinoma Mortality: A Cluster-Randomized Controlled Trial.
    J Clin Oncol. 2024 Oct 1:JCO2301296. doi: 10.1200/JCO.23.01296.
    >> Share

    September 2024
  22. WIRTH LJ, Brose MS, Subbiah V, Worden F, et al
    Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
    J Clin Oncol. 2024;42:3187-3195.
    >> Share

    August 2024
  23. GARDEN AS
    Selecting Patients With Oropharyngeal Cancer for Lower Dose Radiation.
    J Clin Oncol. 2024;42:2835-2836.
    >> Share

    July 2024
  24. DZIENIS M, Cundom J, Fuentes CS, Spreafico A, et al
    Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.
    J Clin Oncol. 2024 Jul 22:JCO2302625. doi: 10.1200/JCO.23.02625.
    >> Share

  25. XIA C, Li H, Chen W
    Reduction in Esophageal Cancer Incidence and Mortality by Screening Endoscopy.
    J Clin Oncol. 2024 Jul 10:JCO2400557. doi: 10.1200/JCO.24.00557.
    >> Share

    June 2024
  26. HEGEWISCH-BECKER S, Mendez G, Chao J, Nemecek R, et al
    First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
    J Clin Oncol. 2024;42:2080-2093.
    >> Share

  27. HUANG CL, Zhang N, Jiang W, Xie FY, et al
    Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial.
    J Clin Oncol. 2024;42:2021-2025.
    >> Share

  28. JANJIGIAN YY, Ajani JA, Moehler M, Shen L, et al
    First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.
    J Clin Oncol. 2024;42:2012-2020.
    >> Share

    May 2024
  29. GILLENWATER AM, Vigneswaran N, Sikora AG
    Assessing the Role of Inflammation in Oral Tongue Carcinogenesis.
    J Clin Oncol. 2024;42:1729-1730.
    >> Share

  30. TIAN Q, Jiang L, Dai D, Liu L, et al
    Impact of Postoperative Radiotherapy on the Prognosis of Early-Stage (pT1-2N0M0) Oral Tongue Squamous Cell Carcinoma.
    J Clin Oncol. 2024;42:1754-1765.
    >> Share

  31. TOTA JE, Engels EA, Lingen MW, Agrawal N, et al
    Inflammatory Tongue Conditions and Risk of Oral Tongue Cancer Among the US Elderly Individuals.
    J Clin Oncol. 2024;42:1745-1753.
    >> Share

  32. JIA R, Shan T, Zheng A, Zhang Y, et al
    Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.
    J Clin Oncol. 2024 May 6:JCO2302009. doi: 10.1200/JCO.23.02009.
    >> Share

  33. WATSON E EE, Hueniken K, Lee J, Huang SH, et al
    Development and Standardization of an Osteoradionecrosis Classification System in Head and Neck Cancer: Implementation of a Risk-Based Model.
    J Clin Oncol. 2024 May 1:JCO2301951. doi: 10.1200/JCO.23.01951.
    >> Share

  34. PETERSON DE, Koyfman SA, Yarom N, Lynggaard CD, et al
    Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy: ISOO-MASCC-ASCO Guideline.
    J Clin Oncol. 2024 May 1:JCO2302750. doi: 10.1200/JCO.23.02750.
    >> Share

    April 2024
  35. WARDILL HR, Bossi P, Sonis ST
    Understanding Protective Mechanisms of an Oral Probiotic in Reducing Radiation-Induced Oral Mucositis.
    J Clin Oncol. 2024;42:1436-1438.
    >> Share

  36. PENG X, Li Z, Pei Y, Zheng S, et al
    Streptococcus salivarius K12 Alleviates Oral Mucositis in Patients Undergoing Radiotherapy for Malignant Head and Neck Tumors: A Randomized Controlled Trial.
    J Clin Oncol. 2024;42:1426-1435.
    >> Share

    March 2024
  37. LEE NY, Sherman EJ, Schoder H, Wray R, et al
    Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma.
    J Clin Oncol. 2024;42:940-950.
    >> Share

  38. LIU M, Yang W, Guo C, Liu Z, et al
    Effectiveness of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: A 9-Year Report of the Endoscopic Screening for Esophageal Cancer in China (ESECC) Randomized Trial.
    J Clin Oncol. 2024 Mar 8:JCO2301284. doi: 10.1200/JCO.23.01284.
    >> Share

    February 2024
  39. ZHU M, Yoon HH
    Neoadjuvant Immunotherapy in Gastroesophageal Cancer: A Promising Early Signal?
    J Clin Oncol. 2024;42:373-377.
    >> Share

    January 2024
  40. SUN R, Liu J, Wei LJ
    Assessing Predictability of Pathologic Lymph Node Regression for Recurrence and Survival in Esophageal Adenocarcinoma.
    J Clin Oncol. 2024;42:366.
    >> Share

    December 2023

  41. Erratum: Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
    J Clin Oncol. 2023 Dec 19:JCO2302629. doi: 10.1200/JCO.23.02629.
    >> Share

    November 2023
  42. LORENZEN S, Gotze TO, Thuss-Patience P, Biebl M, et al
    Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results From the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial.
    J Clin Oncol. 2023 Nov 14:JCO2300975. doi: 10.1200/JCO.23.00975.
    >> Share

    October 2023
  43. MOORE JL, Green M, Santaolalla A, Deere H, et al
    Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom.
    J Clin Oncol. 2023;41:4522-4534.
    >> Share

  44. FARON M, Cheugoua-Zanetsie M, Tierney J, Thirion P, et al
    Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma.
    J Clin Oncol. 2023;41:4535-4547.
    >> Share

    September 2023
  45. KIM CG, Jung M, Kim HS, Lee CK, et al
    Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
    J Clin Oncol. 2023;41:4394-4405.
    >> Share

  46. KEAM B, Hong MH, Shin SH, Heo SG, et al
    Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
    J Clin Oncol. 2023 Sep 12:JCO2202786. doi: 10.1200/JCO.22.02786.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016